An optimized synthesis of 18F-labelled 5-fluorouracil and a reevaluation of its use as a prognostic agent.
An optimized synthesis of 18F-labelled 5-fluorouracil (5-FU) is described. The biodynamics of this radiopharmaceutical were studied in nude mice bearing a 5-FU sensitive (colon 38 carcinoma) or a 5-FU resistant (R1-rhabdomyosarcoma) tumour. It was found that not the initial tumour uptake, but the efflux of the 18F activity from the tumour was correlated with the 5-FU sensitivity of the tumour.
Visser
G W
GW
Radio-Nuclide-Centre, Free University, Amsterdam, The Netherlands.
Gorree
G C
GC
Braakhuis
B J
BJ
Herscheid
J D
JD
D000818:Animals; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D004354:Drug Screening Assays, Antitumor / Q000379:methods; D005472:Fluorouracil / Q000138:chemical synthesis* / Q000378:metabolism / Q000493:pharmacokinetics; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D012208:Rhabdomyosarcoma / Q000188:drug therapy / Q000378:metabolism*; D014018:Tissue Distribution
D005472:Fluorouracil